COVID-19 and Fungal infections : a double debacle
Copyright © 2022 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved..
Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Microbes and infection - 24(2022), 8 vom: 15. Nov., Seite 105039 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mina, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 11.11.2022 Date Revised 06.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.micinf.2022.105039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345474724 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345474724 | ||
| 003 | DE-627 | ||
| 005 | 20231226025133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.micinf.2022.105039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345474724 | ||
| 035 | |a (NLM)36030024 | ||
| 035 | |a (PII)S1286-4579(22)00109-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mina, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and Fungal infections |b a double debacle |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.11.2022 | ||
| 500 | |a Date Revised 06.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Fungal infections remain hardly treatable because of unstandardized diagnostic tests, limited antifungal armamentarium, and more specifically, potential toxic interactions between antifungals and immunosuppressants used during anti-inflammatory therapies, such as those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal infections constitutes a double debacle for patients, healthcare experts, and the public economy. Since the first appearance of SARS-CoV-2, a significant rise in threatening fungal co-infections in COVID-19 patients has been testified in the scientific literature. Better management of fungal infections in COVID-19 patients is, therefore, a priority and requires highlighting common risk factors, relationships with immunosuppression, as well as challenges in fungal diagnosis and treatment. The present review attempts to highlight these aspects in the three most identified causative agents of fungal co-infections in COVID-19 patients: Aspergillus, Candida, and Mucorales species | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aspergillus | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Candida | |
| 650 | 4 | |a Fungal infections | |
| 650 | 4 | |a Mucoromycetes | |
| 650 | 4 | |a Pneumocystis | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Yaakoub, Hajar |e verfasserin |4 aut | |
| 700 | 1 | |a Annweiler, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Dubée, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Papon, Nicolas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microbes and infection |d 1999 |g 24(2022), 8 vom: 15. Nov., Seite 105039 |w (DE-627)NLM105022780 |x 1769-714X |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:8 |g day:15 |g month:11 |g pages:105039 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.micinf.2022.105039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 8 |b 15 |c 11 |h 105039 | ||